The pediatric sepsis biomarker risk model: potential implications for sepsis therapy and biology

Expert Rev Anti Infect Ther. 2014 Jul;12(7):809-16. doi: 10.1586/14787210.2014.912131. Epub 2014 Apr 22.

Abstract

Sepsis remains a major cause of morbidity and mortality in adult and pediatric intensive care units. Heterogeneity of demographics, comorbidities, biological mechanisms, and severity of illness leads to difficulty in determining which patients are at highest risk of mortality. Determining mortality risk is important for weighing the potential benefits of more aggressive interventions and for deciding whom to enroll in clinical trials. Biomarkers can be used to parse patients into different risk categories and can outperform current methods of patient risk stratification based on physiologic parameters. Here we review the Pediatric Sepsis Biomarker Risk Model that has also been modified and applied to estimate mortality risk in adult patients. We compare the two models and speculate on the biological implications of the biomarkers in patients with sepsis.

Keywords: PERSEVERE; biomarker; pediatric; risk stratification; sepsis.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Adult
  • Biomarkers / blood
  • Chemokine CCL3 / blood
  • Chemokine CCL4 / blood
  • Child
  • Decision Trees
  • Granzymes / blood*
  • HSP70 Heat-Shock Proteins / blood
  • Humans
  • Intensive Care Units, Pediatric
  • Interleukin-1alpha / blood
  • Interleukin-8 / blood
  • Matrix Metalloproteinase 8 / blood
  • Models, Theoretical
  • Prognosis
  • Risk Factors
  • Sepsis / blood
  • Sepsis / diagnosis*

Substances

  • Biomarkers
  • Chemokine CCL3
  • Chemokine CCL4
  • HSP70 Heat-Shock Proteins
  • Interleukin-1alpha
  • Interleukin-8
  • Granzymes
  • Matrix Metalloproteinase 8